These data suggest that doxo-treated colon cancer cells exhibit dynamic changes in CD24, CD133 and CD44 antigen presentation, which may have the impact on e.g. the efficacy of CSC-targeted immunotherapy. The gene discussed is CD24; the disease is colonic neoplasm.